FYI From Human Genome Sciences: GlaxoSmithKline Announces New Data From Phase 3 Studies Of Once-Weekly Albiglutide In Type 2 Diabetes
Attached is a
release issued earlier this morning by GlaxoSmithKline,
announcing that detailed findings from the Harmony 6 Phase 3 study
comparing albiglutide to prandial insulin (Lispro), were presented today
Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that detailed findings from the Harmony 6 Phase 3 study comparing albiglutide to prandial insulin (Lispro), were presented today at the American Diabetes Association Meeting (ADA) in Philadelphia, USA, and show that the effect is maintained out to 52 weeks. Results from the Harmony 7 Phase 3 study comparing albiglutide (50 mg) to once-daily liraglutide (1.8 mg) were also presented. Albiglutide, an investigational once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, was created by HGS using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million – including $33.0 million received to date – in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized. All inquiries regarding the albiglutide Phase 3 data announced today should be directed to the contacts provided by GSK. Human Genome Sciences exists to place new therapies into the hands of those battling serious disease. For more information about HGS, please direct inquiries to the HGS contacts provided, or visit the Company’s web site at www.hgsi.com. HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners. SAFE HARBOR STATEMENT This announcement includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those regarding our expectations for albiglutide, among others. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this announcement, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.